Abbott Laboratories NYSE:ABT Rises on In-Line Q2 and Raised Guidance
Abbott Labs Q2 2026 earnings met expectations, slightly beating EPS estimates. The company raised its full-year guidance, boosting investor confidence and driving pre-market gains over 3%.
Read the full article20h agoen
You might also wanna read
Abbott Laboratories (ABT) Q2 2026 Earnings Call Highlights: Strong Growth in Key Segments and .
Abbott Laboratories (ABT) reports robust sales growth and raises full-year EPS guidance, driven by strong performance in Nutrition, Medical
GuruFocus·11h ago
Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
Abbott's Q2 results show solid organic growth, better-than-expected margins, and improved earnings guidance, easing concerns over the Exact
marketbeat.com·19h ago
Abbott (ABT) Receives Outperform Rating Amid Positive Q2 Results
Related Stocks: ABT
GuruFocus·11h ago
Health stocks today: Abbott (NYSE: ABT) jumps 11% as insurers split
NEW YORK, July 16, 2026, 14:23 (EDT). U.S. markets open. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) rose 2.2% to $161.81. The S
ts2.tech·14h ago
Abbott raises 2026 profit forecast on strength in diagnostics, heart devices
Abbott’s quarterly sales in its medical devices segment grew 9% to US$5.85 billion
The Business Times·19h ago
Abbott Laboratories (ABT) Shares Fall 3.4% -- What GF Score of 76 Tells Investors
Related Stocks: ABT
GuruFocus·2d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.